EverPoint Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

EverPoint Asset Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$33.5M	Buy	+405,000	New	+$34.8M	0.62%	36
2015 Q2	–	Sell	-80,000	Closed	-$9.97M	–	453
2015 Q1	$9.97M	Sell	80,000 -20,000	-20%	-$2.12M	0.19%	170
2014 Q4	$9.04M	Sell	100,000 -215,000	-68%	-$17.9M	0.2%	166
2014 Q3	$22.7M	Buy	315,000 +37,329	+13%	+$2.45M	0.52%	43
2014 Q2	$17.3M	Buy	+277,671	New	+$16.8M	0.36%	67

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EverPoint Asset Management's BMRN Position: Q4 2016 in Review

EverPoint Asset Management opened a new position in BioMarin Pharmaceuticals (BMRN) in Q4 2016: 405,000 shares worth $33.5M. The stake represents 0.62% of the portfolio and ranks #36 among its holdings. This is a return to the name: EverPoint Asset Management previously reported a position in BMRN as recently as Q1 2015.

EverPoint Asset Management first reported a position in BMRN in Q2 2014 and has held it in 5 quarters since. 415 funds tracked by Wall St. Rank hold BMRN as of Q4 2016.

EverPoint Asset Management held 405,000 shares of BioMarin Pharmaceuticals worth $33.5M as of Q4 2016.
BioMarin Pharmaceuticals was a new EverPoint Asset Management position in Q4 2016.
BioMarin Pharmaceuticals made up 0.62% of EverPoint Asset Management's portfolio in Q4 2016, its #36 holding.
EverPoint Asset Management first reported a position in BioMarin Pharmaceuticals in Q2 2014 and has held it in 5 quarters since.
415 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2016.

Based on EverPoint Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.